Reduced levels of interleukin 33 and increased levels of soluble ST2 in subjects with amyotrophic lateral sclerosis

Journal of Neuroimmunology

Volumn 249, Issue 1-2, 2012, Pages 93-95

  Lin, C Y ^a   Pfluger, C M ^a   Henderson, R D ^a   McCombe, P A ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Amyotrophic lateral sclerosis; Apoptosis; Cytokines; Interleukin 33; Neuroinflammation; Soluble ST2

Indexed keywords

CASPASE; INTERLEUKIN 33; INTERLEUKIN RECEPTOR; PROTEIN ST2; UNCLASSIFIED DRUG;

ADULT; AMYOTROPHIC LATERAL SCLEROSIS; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME RELEASE; FEMALE; HUMAN; HUMAN CELL; INTERLEUKIN 33 BLOOD LEVEL; MALE; NERVOUS SYSTEM INFLAMMATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN DETERMINATION; PROTEIN ST2 BLOOD LEVEL;

AMYOTROPHIC LATERAL SCLEROSIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERLEUKINS; MALE; MIDDLE AGED; RECEPTORS, CELL SURFACE;

EID: 84863464689     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2012.05.001     Document Type: Article

References (28)

1. Arend W.P., Palmer G., Gabay C. IL-1, IL-18, and IL-33 families of cytokines. Immunol. Rev. 2008, 223:20-38.
2. Bhardwaj A., Januzzi J.L. ST2: a novel biomarker for heart failure. Expert. Rev. Mol. Diagn. 2010, 10:459-464.
3. Brooks B.R., Miller R.G., Swash M., Munsat T.L. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 2000, 1:293-299.
4. Carriere V., Roussel L., Ortega N., et al. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:282-287.
5. Christophi G.P., Gruber R.C., Panos M., Christophi R.L., Jubelt B., Massa P.T. Interleukin-33 upregulation in peripheral leukocytes and CNS of multiple sclerosis patients. Clin. Immunol. 2012, 142:308-319.
6. Fousteris E., Melidonis A., Panoutsopoulos G., et al. Toll/interleukin-1 receptor member ST2 exhibits higher soluble levels in type 2 diabetes, especially when accompanied with left ventricular diastolic dysfunction. Cardiovasc. Diabetol. 2011, 10:101.
7. Han G.W., Zeng L.W., Liang C.X., et al. Serum levels of IL-33 is increased in patients with ankylosing spondylitis. Clin. Rheumatol. 2011, 30:1583-1588.
8. Han P., Mi W.L., Wang Y.Q. Research progress on interleukin-33 and its roles in the central nervous system. Neurosci. Bull. 2011, 27:351-357.
9. Hawari F.I., Rouhani F.N., Cui X., et al. Release of full-length 55-kDa TNF receptor 1 in exosome-like vesicles: a mechanism for generation of soluble cytokine receptors. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:1297-1302.
10. Henkel J.S., Engelhardt J.I., Siklos L., et al. Presence of dendritic cells, MCP-1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue. Ann. Neurol. 2004, 55:221-235.
11. Hong Y.S., Moon S.J., Joo Y.B., et al. Measurement of interleukin-33 (IL-33) and IL-33 receptors (sST2 and ST2L) in patients with rheumatoid arthritis. J. Korean Med. Sci. 2011, 26:1132-1139.
12. Hudson C.A., Christophi G.P., Gruber R.C., Wilmore J.R., Lawrence D.A., Massa P.T. Induction of IL-33 expression and activity in central nervous system glia. J. Leukoc. Biol. 2008, 84:631-643.
13. Ilzecka J. Serum caspase-9 levels are increased in patients with amyotrophic lateral sclerosis. Neurol. Sci. 2011, 10.1007/s10072-011-0837-4.
14. Iwahana H., Yanagisawa K., Ito-Kosaka A., et al. Different promoter usage and multiple transcription initiation sites of the interleukin-1 receptor-related human ST2 gene in UT-7 and TM12 cells. Eur. J. Biochem. 1999, 264:397-406.
15. Lohning M., Stroehmann A., Coyle A.J., et al. T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:6930-6935.
16. McCombe P.A., Henderson R.D. The role of immune and inflammatory mechanisms in ALS. Curr. Mol. Med. 2011, 11:246-254.
17. Mildner M., Storka A., Lichtenauer M., et al. Primary sources and immunological prerequisites for sST2 secretion in humans. Cardiovasc. Res. 2010, 87:769-777.
18. Miller A.M. Role of IL-33 in inflammation and disease. J. Inflamm. (Lond) 2011, 8:22.
19. Miyagaki T., Sugaya M., Yokobayashi H., et al. High levels of soluble ST2 and low levels of IL-33 in sera of patients with HIV infection. J. Invest. Dermatol. 2011, 131:794-796.
20. Mok M.Y., Huang F.P., Ip W.K., et al. Serum levels of IL-33 and soluble ST2 and their association with disease activity in systemic lupus erythematosus. Rheumatology (Oxford) 2010, 49:520-527.
21. Oliphant C.J., Barlow J.L., McKenzie A.N. Insights into the initiation of type 2 immune responses. Immunology 2011, 134:378-385.
22. Oppenheim J.J., Tewary P., de la R.G., Yang D. Alarmins initiate host defense. Adv. Exp. Med. Biol. 2007, 601:185-194.
23. Palmer G., Gabay C. Interleukin-33 biology with potential insights into human diseases. Nat. Rev. Rheumatol. 2011, 7:321-329.
24. Rothstein J.D. Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann. Neurol. 2009, 65(Suppl. 1):S3-S9.
25. Sathasivam S., Ince P.G., Shaw P.J. Apoptosis in amyotrophic lateral sclerosis: a review of the evidence. Neuropathol. Appl. Neurobiol. 2001, 27:257-274.
26. Yamanaka K., Chun S.J., Boillee S., et al. Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat. Neurosci. 2008, 11:251-253.
27. Yasuoka S., Kawanokuchi J., Parajuli B., et al. Production and functions of IL-33 in the central nervous system. Brain Res. 2011, 1385:8-17.
28. Zhao W., Hu Z. The enigmatic processing and secretion of interleukin-33. Cell. Mol. Immunol. 2010, 7:260-262.